MedTrace Logo

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

NCT00303290 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2015-11-26

No results posted yet for this study

Summary

The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Peg Interferon Alpha 2b (Peg Intron)

4.5 micrograms/kg once a week

DRUG

Ara-C (cytosine arabinoside)

10 mg under the skin daily

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jorge E Cortes, MD · The University of Texas N.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00303290 on ClinicalTrials.gov